Phase 3 Clinical Trials – Page 5

AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

11 months ago talkbio0Tagged AVEO, Fotivda, Malignant neoplasm of kidney, Neoplasms, nivolumab, Phase 3 Clinical Trials, Renal Cell Carcinoma, tivozanib

AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

11 months ago talkbio0Tagged Accelerated, Agenus, Approved, balstilimab, Botensilimab, Colorectal Carcinoma, Combined, Immunotherapy, Partnership, Phase 3 Clinical Trials, United States Food and Drug Administration

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership

Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

11 months ago talkbio0Tagged Annovis, Bio, buntanetap, Cognition, MDS-UPDRS, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Parkinson 's Disease Rating Scale, Phase 3 Clinical Trials, Unified - Type of Agreement

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study

12 months ago talkbio0Tagged AstraZeneca, Disease-Free Survival, Imfinzi, Malignant neoplasm of lung, Malignant neoplasm of urinary bladder, Phase 3 Clinical Trials

AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival

Merck KGaA Discontinues Xevinapant Program in Locally Advanced Head and Neck Cancer Due to Phase III Trial Failure

12 months ago talkbio0Tagged Apoptosis, Cancer of Neck, Merck KGaA, Oncology Pipeline, Phase 3 Clinical Trials, proteins inhibitor, X-Ray Vision study

Merck KGaA, xevinapant, Phase III trial, head and neck cancer, TrilynX study, X-Ray Vision study, oncology pipeline, apoptosis proteins inhibitor

Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer

12 months ago talkbio0Tagged Cancer of Neck, Discontinuation (procedure), Malignant Neoplasms, Merck KGaA, Phase 3 Clinical Trials, Xevinapant

Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment

Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment

12 months ago talkbio0Tagged Antipsychotic Agents, Caplyta, Intra-Cellular Therapies, Lumateperone, Mental Depression, Phase 3 Clinical Trials

Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment

AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial

12 months ago talkbio0Tagged AKT1 protein, human, AstraZeneca, CAPItello-290, capivasertib, Overall Survival, paclitaxel, Phase 3 Clinical Trials, PIK3CA gene, PTEN gene, Triple Negative Breast Neoplasms, Truqap

AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN

Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results

1 year ago talkbio0Tagged Agonist, Narcolepsy, Narcolepsy type 1, Phase 3 Clinical Trials, TAK-861, Takeda

Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

1 year ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor